4. Travel vaccine schedules
The Travel Vaccination schedule has been compiled by TRAVAX.
The table lists the individual vaccination schedules. This information is also available from the individual vaccine SPCs. It can be used to plan a vaccination schedule as part of your travel advice.
Please note this information will be subject to change. Please check NumarkNet travel pages for updates on malaria and disease prevalence. You can download and check the schedule as part of your vaccination advice.
|
Vaccine |
Trade Name (Vaccine Type) |
Primary Schedule |
Booster or Revaccination |
Children |
Comments |
|
Cholera |
Dukoral® (Inactivated bacterial) |
6 yrs and over 2 doses oral (150ml): 1-6 weeks apart |
Boost at 2 yrs adults and children> 6 yrs Children 2-6 yrs boost at 6 months If > 2 yrs restart schedule |
2-6 yrs 3 doses (75ml) at 0, +1, +2 weeks >6 yrs 2 doses (150ml): 1-6 weeks apart |
Nil by mouth for 1 hour before and after Dukoral® If > 6 weeks between doses, restart schedule. Protects 1 week after final dose |
|
Diphtheria |
Revaxis® (Inactivated viral and toxoid) |
10 yrs and over 3 doses 0.5ml IM 1 month apart |
Boost at 10 year intervals |
Can be used from 10 yrs of age (see UK schedule) |
|
|
Hepatitis A |
Avaxim® Havrix monodose® VAQTA Adult® (Inactivated viral) |
Adults 1 dose 0.5ml IM or 1 dose 1.0ml IM |
Boost between 6 to 12 months (6-18 months for VAQTA) to give protection for 25 years. It is however unnecessary to restart the primary course if booster given within 5 years |
Avaxim® and Havrix® from 16 yrs old, VAQTA® from 18 yrs old. Protects for 1 year 2-4 weeks after first dose and 25 years after 2nd dose. |
|
|
Hepatitis A (Paediatric) |
Havrix Junior monodose® VAQTA® Paediatric (Inactivated viral) |
1 yr and over 1 dose 0.5ml IM |
Boost between 6 – 12 months to give at least 25 years protection |
Havrix 1-15yrs VAQTA 1-17yrs |
Protects for 1 year 2-4 weeks after first dose and 25 years after 2nd dose |
|
Hepatitis A Typhoid |
Viatim® (Inactivated/Polysaccharide) |
16yrs and over 1 dose 1.0ml IM |
Boost hepatitis A between 6- 12 months. Boost typhoid at 3 yrs |
No 16+ yrs |
Protective levels from 2 weeks |
|
Hepatitis B |
Engerix B® HBVAXPRO® 10mcg (Recombinant viral) |
16yrs and over 3 doses 1.0ml IM at 0, 1, 6 months or rapid schedule 0, 1, 2, months |
The full duration of protection has yet to be established. Individuals at continuing risk should be offered a single booster dose at 5 years (once only). |
No 16+ yrs |
Engerix B® has a more rapid schedule of day 0, 7, 21 with a fourth dose at 1 year. |
|
Hepatitis B (Paediatric) |
Engerix B® HBVAXPRO® 5mcg (Recombinant viral) |
3 doses 0.5ml IM at 0, 1, 6 months or rapid scheduleor 0, 1, 2, months with 4th dose at 12 months for infants at increased risk |
Children born to HBV positive mothers should have a booster dose at school entry. |
Birth to 15 yrs |
Engerix B® has 2 dose schedule for 11-15 year olds at 0,6 months Infants born after 1st August 2017 will receive vaccination as part of the childhood schedule |
|
Hepatitis A/B |
Twinrix® (Inactivated and recombinant viral) |
16 yrs and over 3 doses 1.0ml IM at 0, 1, 6 months |
See hepatitis A and hepatitis B |
No 16+ yrs |
If time is short a rapid schedule of day 0, 7, 21 may be used with a fourth dose at 1 year (licensed from 18yrs only). |
|
Hepatitis A/B (Paediatric) |
Twinrix® Paediatric Vaccine Ambirix® (Inactivated and recombinant viral) |
1 yr and over Twinrix ® 3 doses 0.5ml IM at 0, 1, 6 months Ambirix®2 doses 1.0ml day 0 and 6-12 months |
See hepatitis A and hepatitis B |
From 1-15yrs |
Ambirix® should only be used when the risk from hepatitis B is relatively low during the vaccination course and where completion of the course can be assured. |
|
Influenza |
Influvac ® (inactivated surface antigen)Fluarix® Fluviron® (Inactivated split viron) FLUENZ® (live attenuated intranasal) |
6 months and over 1 dose 0.5ml IM/SC Single application in each nostril of 0.1ml |
Annually |
From 6 months old |
|
|
Japanese Encephalitis |
IXIARO® (Inactivated viral) |
3 yrs and over 2 doses 0.5ml IM on day 0, 28 Rapid schedule (18-64 years old) 2 doses at 0.7 days |
Booster at 12 months if at continuous risk. All others, boost between 12-24 months. 2nd booster for aged 18-64 10 years after first booster if continued risk |
Children 2 months to 3 years give 0.25ml |
Rapid schedule can be used off license for children from 2 months to 17 years of age and adults 65 years of age and older |
|
Japanese Encephalitis |
Japanese encephalitis (JE) Vaccine – GCVC® (Inactivated viral) |
3 yrs and over 3 doses 1.0ml SC on day 0, 7, 28 |
After 1 yr then every 3 yrs |
Children under 3 yrs – 3 doses 0.5ml SC |
A rapid schedule can be given as 2 doses on day 0, 7-14 or 3 doses on days 0,7,14 but results in limited seroconversion and protection of shorter duration. Caution in those with unstable neurological conditions, particularly seizures within last year (JE Vaccine). ** |
|
Measles/ Mumps/ Rubella |
MMRVaxPro® Priorix® (live attenuated) |
1 dose 0.5ml SC/IM |
Unimmunised adults should receive a 2nd dose after 1 month |
Children should receive 2 doses at 13 months & 3 ½ yrs |
Pregnancy should be avoided for 1 month after MMR If high risk children are vaccinated before 1 yr they should receive a 2nd dose at 15 months and a further dose given at the usual time.† MMR and Yellow fever should be given 4 weeks apart |
|
Meningococal ACWY |
Menveo® Group A, C, W135 and Y (Conjugate bacterial) Nimenrix® Group A, C, W135 and Y (Conjugate bacterial) |
1 yr and over 1 dose 0.5ml IM |
Menveo® Children 2 months to 1 year and Nimenrix ® 6months to 1 year 2 doses at 0 and +1 month |
||
|
Poliomyelitis |
Revaxis® (Inactivated viral and toxoid) |
10 years and over 3 doses 0.5 ml IM 1 month apart |
Boost at 10 year intervals |
Can be used from 10 yrs of age (see UK schedule) |
|
|
Rabies |
Rabipur® Rabies Vaccine BP (Inactivated viral) |
3 doses 1.0ml IM on day 0, 7 and 28 (can be given on day 21 if time is short) Rapid schedule: |
Booster not recommended for most travellers. Single booster dose can be considered, following a risk assessment, if completed a primary course over one year ago and travelling again to a high risk area*** |
No lower age limit stated. |
Rabipur® is contraindicated if hypersensitive to egg. Caution in bleeding disorders. |
|
Tetanus |
Revaxis® (Inactivated viral and toxoid) |
10 yrs and over 3 doses 0.5 ml IM 1 month apart |
Boost at 10 year intervals |
Can be used from 10 yrs of age (see UK schedule) |
|
|
Tick-borne encephalitis |
TicoVac® TicoVac Junior® (Inactivated viral) |
16 yrs and over 3 doses 0.5 ml IM on day 0, 1-3 months and 5-12 months after 2nd dose
Rapid schedule 3 doses on days 0,14 and 5-12 months after 2nd dose |
Booster within 3 yrs of 3rd dose, then 3-5 yrly if at continuous risk |
Children 1-16 yrs TicoVac® Junior, 3 doses 0.25 ml same schedule as adults. |
TicoVac® is contraindicated if hypersensitive to egg. Sufficient protection for 6-12 months is achieved after 2nd dose, 3rd dose ensures protection for 3 years |
|
Tuberculosis (BCG) |
BCG Vaccine SSI (Live attenuated bacterial) |
1 yr and over 1 dose 0.1ml ID |
Protection lasts for 10-15 years, no evidence of further protection from booster |
Children under 1 yr, 1 dose 0.05ml ID |
No further vaccinations in the BCG arm for 3 months. Green Book - Children under 6 yrs do not require skin testing prior to BCG unless exposure is suspected. |
|
Typhoid |
Typhim Vi® (Polysaccharide bacterial) Vivotif® (live attenuated, oral) |
2 yrs and over1 dose 0.5ml IM 6 yrs and over 3 oral capsules on day 1/3/5 |
Booster after 3 yrs |
Typhim Vi® can be given from 2 yrs. Vivotif® from 6yrs to adult |
Protective levels from 2 weeks for Typhim ® Protective level 7-10 days after 3rd dose for Vivotif® |
|
Yellow Fever |
Stamaril® (Live attenuated viral) |
9 months and over 1 dose 0.5ml SC preferred (or IM) |
Booster not routinely recommended as immunity considered lifelong* |
Children from 9 months same as adult dose. Contraindicated in children under 6 months. Children from 6-9 months only in special circumstances (during major outbreaks) |
In persons aged 60 years or older, the vaccine should only be considered if there is a clear and unavoidable risk of acquiring yellow fever infection From 11 July 2016 (for all countries), the yellow fever vaccine certificate (ICVP) will be valid for the duration of the life of the person vaccinated. Certificate valid from 10 days after immunisation^ |
† Green Book states that infants from 6 months of age travelling to endemic areas or areas with current outbreak, should receive an MMR vaccine with a further 2 doses given at the recommended ages. Children who are travelling who have received 1 dose at the routine age should have the 2nd dose brought forward to at least 1 month after the 1st. If the child is under 18 months of age and the 2nd dose is given within 3 months of the 1st dose, then the pre-school dose (3rd) should be given to ensure full protection.
** Green Book – Anecdotal reports suggest that JE vaccine should not be used in individuals who have recovered from acute disseminated encephalomyelitis or Guillain-Barre syndrome or who have multiple sclerosis or other demyelinating disorders (Plotkin and Orenstein, 2004)
*** Green Book –The requirement for booster doses is dependent on an individual’s indication for preexposure prophylaxis and the likely frequency of ongoing exposures. In those who may have frequent unrecognised exposures to the virus, e.g. bat handlers, a single reinforcing dose of vaccine should be given one year after the primary course has been completed. Further booster doses should then be given every three to five years or based on serology
* The WHO Strategic Advisory Group of Experts (SAGE) on Immunization state that (based on currently available data, a single dose of yellow fever vaccine appears to confer life-long protective immunity against yellow fever disease. Therefore, with some exceptions, a booster dose of yellow fever vaccine is not needed to maintain immunity (WHO Strategic Advisory Group of Experts (SAGE), 2013).
^WHO state that a valid certificate, presented by arriving travellers, cannot be rejected on the grounds that more than ten years have passed since the date vaccination became effective as stated on the certificate; and that boosters or revaccination cannot be required (WHO, 2016).
Last updated: 26th May 2021
Source: http://www.travax.nhs.uk